PURPOSE: To evaluate the psychometric properties of the original Parent and new Child Amblyopia Treatment Index (ATI), questionnaires that assess the burden of amblyopia treatment in children and families, and to compare scores between children treated with atropine or patching. METHODS: Parent ATI and Child ATI were administered to 233 children 7 to <13 years old and their parents as part of a randomized trial comparing patching and atropine for amblyopia treatment. For each ATI version, construct validity was assessed using factor analysis; internal consistency reliability was assessed using Cronbach's alpha. Data from the Parent ATI and Child ATI were correlated and scores for each version were compared between treatment groups. RESULTS: We analyzed the 3 subscales found in prior Parent ATI studies in younger children and confirmed subscales for adverse effects and treatment compliance, but not for social stigma, in both parent and child versions. Overall and subscale scores on the Parent ATI and Child ATI were moderately to well correlated except for the social stigma subscale. For both the Parent ATI and the Child ATI, children treated with atropine had better scores than those treated with patching, both overall and on treatment compliance and social stigma subscales (all p values ≤ 0.01). CONCLUSIONS: When used for children 7 to <13 years old, the Parent ATI and Child ATI have similar factor structures to each other and to the Parent ATI for children 3 to <7 years old. Atropine treatment was found to have less negative impact than patching.
RCT Entities:
PURPOSE: To evaluate the psychometric properties of the original Parent and new ChildAmblyopia Treatment Index (ATI), questionnaires that assess the burden of amblyopia treatment in children and families, and to compare scores between children treated with atropine or patching. METHODS: Parent ATI and ChildATI were administered to 233 children 7 to <13 years old and their parents as part of a randomized trial comparing patching and atropine for amblyopia treatment. For each ATI version, construct validity was assessed using factor analysis; internal consistency reliability was assessed using Cronbach's alpha. Data from the Parent ATI and ChildATI were correlated and scores for each version were compared between treatment groups. RESULTS: We analyzed the 3 subscales found in prior Parent ATI studies in younger children and confirmed subscales for adverse effects and treatment compliance, but not for social stigma, in both parent and child versions. Overall and subscale scores on the Parent ATI and ChildATI were moderately to well correlated except for the social stigma subscale. For both the Parent ATI and the ChildATI, children treated with atropine had better scores than those treated with patching, both overall and on treatment compliance and social stigma subscales (all p values ≤ 0.01). CONCLUSIONS: When used for children 7 to <13 years old, the Parent ATI and ChildATI have similar factor structures to each other and to the Parent ATI for children 3 to <7 years old. Atropine treatment was found to have less negative impact than patching.
Authors: S R Cole; R W Beck; P S Moke; M P Celano; C D Drews; M X Repka; J M Holmes; E E Birch; R T Kraker; K E Kip Journal: J AAPOS Date: 2001-08 Impact factor: 1.220
Authors: Michael X Repka; Susan A Cotter; Roy W Beck; Raymond T Kraker; Eileen E Birch; Donald F Everett; Richard W Hertle; Jonathan M Holmes; Graham E Quinn; Nicholas A Sala; Mitchell M Scheiman; David R Stager; David K Wallace Journal: Ophthalmology Date: 2004-11 Impact factor: 12.079
Authors: Jonathan M Holmes; Raymond T Kraker; Roy W Beck; Eileen E Birch; Susan A Cotter; Donald F Everett; Richard W Hertle; Graham E Quinn; Michael X Repka; Mitchell M Scheiman; David K Wallace Journal: Ophthalmology Date: 2003-11 Impact factor: 12.079
Authors: Michael X Repka; Roy W Beck; Jonathan M Holmes; Eileen E Birch; Danielle L Chandler; Susan A Cotter; Richard W Hertle; Raymond T Kraker; Pamela S Moke; Graham E Quinn; Mitchell M Scheiman Journal: Arch Ophthalmol Date: 2003-05
Authors: Jonathan M Holmes; Roy W Beck; Raymond T Kraker; Stephen R Cole; Michael X Repka; Eileen E Birch; Joost Felius; Stephen P Christiansen; David K Coats; Marjean T Kulp Journal: Arch Ophthalmol Date: 2003-11
Authors: Jonathan M Holmes; Samara Strauber; Graham E Quinn; Stephen R Cole; Joost Felius; Marjean Kulp Journal: J AAPOS Date: 2008-10-30 Impact factor: 1.220
Authors: Mitchell M Scheiman; Richard W Hertle; Raymond T Kraker; Roy W Beck; Eileen E Birch; Joost Felius; Jonathan M Holmes; James Kundart; David G Morrison; Michael X Repka; Susanna M Tamkins Journal: Arch Ophthalmol Date: 2008-12
Authors: Tina Y Gao; Cindy X Guo; Raiju J Babu; Joanna M Black; William R Bobier; Arijit Chakraborty; Shuan Dai; Robert F Hess; Michelle Jenkins; Yannan Jiang; Lisa S Kearns; Lionel Kowal; Carly S Y Lam; Peter C K Pang; Varsha Parag; Roberto Pieri; Rajkumar Nallour Raveendren; Jayshree South; Sandra Elfride Staffieri; Angela Wadham; Natalie Walker; Benjamin Thompson Journal: JAMA Ophthalmol Date: 2018-02-01 Impact factor: 7.389
Authors: Eileen E Birch; Yolanda S Castañeda; Christina S Cheng-Patel; Sarah E Morale; Krista R Kelly; Cynthia L Beauchamp; Ann Webber Journal: JAMA Ophthalmol Date: 2019-02-01 Impact factor: 7.389